All lobbying filings

RARE DISEASE COMPANY COALITION

RARE DISEASE COMPANY COALITION filed a Q1 report for RARE DISEASE COMPANY COALITION on April 20, 2026.

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

All filings by RARE DISEASE COMPANY COALITION · Everything RARE DISEASE COMPANY COALITION has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$110,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

GABBI SALMON New on this filing

Previously held: Legislative Intern, Sen. Lamar Alexander.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Trade (domestic/foreign)

Proclamation 11020 - Section 232 Pharmaceutical Tariffs

Bills named in this filing 2

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
H.R. 1762
Forest Service Accountability Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.